Sterling Investment Advisors Ltd. Decreases Holdings in Johnson & Johnson $JNJ

Key Points

• Sterling Investment Advisors Ltd. reduced its holdings in Johnson & Johnson by 4.2% in Q2, owning 34,097 shares valued at approximately $5.21 million.
• Multiple analysts have recently revised their price targets for Johnson & Johnson, with Citigroup and JPMorgan both raising their targets to $200, indicating optimism about the stock's performance.
• Johnson & Johnson declared a quarterly dividend of $1.30 per share, reflecting an annual yield of 2.8% and a dividend payout ratio of 55.61%.

Sterling Investment Advisors Ltd. decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,097 shares of the company's stock after selling 1,484 shares during the period. Johnson & Johnson accounts for 1.2% of Sterling Investment Advisors Ltd.'s holdings, making the stock its 23rd biggest position. Sterling Investment Advisors Ltd.'s holdings in Johnson & Johnson were worth $5,208,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Raleigh Capital Management Inc. lifted its position in Johnson & Johnson by 7.3% during the second quarter. Raleigh Capital Management Inc. now owns 14,777 shares of the company's stock valued at $2,257,000 after acquiring an additional 1,005 shares during the last quarter. Claris Advisors LLC MO lifted its position in Johnson & Johnson by 57.4% during the second quarter. Claris Advisors LLC MO now owns 3,437 shares of the company's stock valued at $525,000 after acquiring an additional 1,254 shares during the last quarter. Smith Chas P & Associates PA Cpas lifted its position in Johnson & Johnson by 2.4% during the second quarter. Smith Chas P & Associates PA Cpas now owns 259,477 shares of the company's stock valued at $39,635,000 after acquiring an additional 6,126 shares during the last quarter. Baron Silver Stevens Financial Advisors LLC raised its holdings in shares of Johnson & Johnson by 3.8% in the second quarter. Baron Silver Stevens Financial Advisors LLC now owns 5,667 shares of the company's stock worth $866,000 after buying an additional 205 shares during the last quarter. Finally, Prepared Retirement Institute LLC raised its holdings in shares of Johnson & Johnson by 23.0% in the second quarter. Prepared Retirement Institute LLC now owns 1,623 shares of the company's stock worth $248,000 after buying an additional 304 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on JNJ. Citigroup raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a report on Thursday, August 21st. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a report on Friday, September 19th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday, September 16th. Finally, Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $181.40.

Johnson & Johnson Stock Up 2.1%

NYSE:JNJ opened at $185.40 on Wednesday. The firm has a market capitalization of $446.51 billion, a P/E ratio of 19.83, a PEG ratio of 2.31 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $185.99. The company's fifty day moving average price is $175.11 and its 200-day moving average price is $162.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.